Placebo + Curcumin

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Bleeding

Conditions

Bleeding, Implants, Breakthrough Bleeding

Trial Timeline

Apr 15, 2020 โ†’ Aug 1, 2023

About Placebo + Curcumin

Placebo + Curcumin is a approved stage product being developed by Merck for Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT04205929. Target conditions include Bleeding, Implants, Breakthrough Bleeding.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04205929ApprovedCompleted

Competing Products

20 competing products in Bleeding

See all competitors
ProductCompanyStageHype Score
60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/NDaiichi SankyoPhase 1
33
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placeboAbbViePhase 2
52
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + ProgesteroneAbbViePhase 2
52
Elagolix + Estradiol /norethindrone acetate (E2/NETA)AbbViePhase 3
77
Risk of selected safety eventsAstraZenecaPre-clinical
23
AnticoagulantAstraZenecaPre-clinical
23
Esomeprazole Na + Cimetidine + Esomeprazole MgAstraZenecaPhase 3
77
Tamoxifen + Placebo + Tamoxifen (open label)MerckApproved
85
Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implantMerckApproved
85
Octreotide LAR DepotNovartisPhase 1
33
activated recombinant human factor VIINovo NordiskPre-clinical
22
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
76
catridecacog + recombinant factor XIIINovo NordiskPhase 1
32
eptacog alfa (activated) + placeboNovo NordiskPhase 3
76
activated recombinant human factor VII + activated recombinant human factor VIINovo NordiskPhase 1
32
activated recombinant human factor VIINovo NordiskPhase 2
51
autologous stored plateletsNovo NordiskPhase 2
51
turoctocog alfa pegolNovo NordiskPhase 3
76
recombinant factor XIIINovo NordiskPre-clinical
22
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
32